

Applicant: Erik Buntinx
Serial No.: 10/752,423
Filed: January 6, 2004
page 2 of 13

Amendments to the Claims:

Please cancel Claims 66 and 67 without prejudice or disclaimer, and amend Claims 1 and 64 as set forth below.

1. (Currently amended) A method for treating an anxiety disorder comprising simultaneously administering to a patient a pharmaceutical composition comprising i) pipamperone in a daily dose ranging between 5 and 15 mg and ii) a selective serotonin re-uptake inhibitor (SSRI), wherein pipamperone is administered in a daily dose ranging between 5 and 15 mg, wherein said simultaneous administration of pipamperone and said SSRI augments the therapeutic effect of said SSRI or provides a faster onset of the therapeutic effect of said SSRI, and wherein said SSRI is chosen from the group consisting of CITALOPRAM, fluoxetine, ~~venlafaxine~~, fluvoxamine, paroxetine, sertraline, milnacipran and duloxetine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.

2-9. (Canceled)

10. (Previously presented) The method of claim 1, wherein said serotonin re-uptake inhibitor is CITALOPRAM and wherein CITALOPRAM is administered in a dose ranging between 10 and 40 mg.

11-63. (Canceled)

64. (Currently amended) A method for treating an anxiety disorder in a patient comprising simultaneously administering to the patient a pharmaceutical composition comprising i) pipamperone in a daily dose ranging between 5 and 15 mg and ii) a selective serotonin re-uptake inhibitor (SSRI), wherein pipamperone is administered in a daily dose ranging between 5 and 15 mg and wherein said SSRI is chosen from the group

Applicant: Erik Buntinx
Serial No.: 10/752,423
Filed: January 6, 2004
page 3 of 13

consisting of CITALOPRAM, fluoxetine, ~~venlafaxine~~, fluvoxamine, paroxetine, sertraline, milnacipran and duloxetine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.

65. (Previously presented) The method of claim 64, wherein said serotonin re-uptake inhibitor is CITALOPRAM and wherein CITALOPRAM is administered in a dose ranging between 10 and 40 mg.

66-67. (Canceled)